-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Povidone Iodine ER in Viral Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povidone Iodine ER in Viral Conjunctivitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povidone Iodine ER in Viral Conjunctivitis Drug Details: Povidone iodine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erlotinib in Palmoplantar Keratoderma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erlotinib in Palmoplantar Keratoderma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erlotinib in Palmoplantar Keratoderma Drug Details: Erlotinib is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-010 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-010 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-010 in B-Cell Non-Hodgkin Lymphoma Drug Details: CB-010 is under development...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drugs In Development, 2023’, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Actinic (Solar) Keratosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Drugs In Development, 2023’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Inherited Skin Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Inherited Skin Disorders - Drugs In Development, 2023’, provides an overview of the Inherited Skin Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inherited Skin Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HMPL-760 in Tenosynovial Giant Cell Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HMPL-760 in Tenosynovial Giant Cell Tumor Drug Details: HMPL-760 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linezolid in Chronic Low Back Pain (CLBP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linezolid in Chronic Low Back Pain (CLBP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linezolid in Chronic Low Back Pain (CLBP) Drug Details:...